Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F PI 2620

Next Previous
Drug Profile

18F PI 2620

Alternative Names: [18F]PI-2620; PI-2620; Tau-PET tracer - AC Immune

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Life Molecular Imaging; The Michael J. Fox Foundation for Parkinson's Research; University of Pennsylvania
  • Class 3-ring heterocyclic compounds; Fluorinated hydrocarbons; Imaging agents; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corticobasal degeneration; Progressive supranuclear palsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease; Dementia
  • Phase II Corticobasal degeneration; Parkinson's disease; Progressive supranuclear palsy
  • Phase I Traumatic brain injuries

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Traumatic-brain-injuries in USA (IV, Injection)
  • 12 May 2025 Phase-II clinical trials in Corticobasal degeneration (Diagnosis) in USA (IV) (NCT07020026)
  • 12 May 2025 Phase-II clinical trials in Progressive supranuclear palsy (Diagnosis) in USA (IV) (NCT07020026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top